Compare AU

Compare CURE vs. HVST

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Australian Dividend Harvester Fund (Managed Fund) (HVST). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

HVST

Popularity

Low

Low

Pearlers invested

83

52

Median incremental investment

$619.50

$993.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$3,228.71

Average age group

> 35

> 35


Key Summary

CURE

HVST

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

HVST.AX was created on 2014-10-29 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 226.57m in AUM and 54 holdings. HVST.AX aims to provide exposure to large-cap Australian shares, along with the potential for franked income that is at least 1.5x the yield of the Australian broad sharemarket on an annual basis.

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

BETASHARES AUSTRALIA 200 ETF (24.70 %)

COMMONWEALTH BANK OF AUSTRALIA (10.55 %)

BETASHARES AUSTRALIAN RESOURCE (9.04 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Other (47.20 %)

Financials (16.27 %)

Health Care (6.88 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Australia (97.05 %)

United States (2.00 %)

United Kingdom of Great Britain and Northern Ireland (0.56 %)

Management fee

0.45 %

0.65 %


Key Summary

CURE

HVST

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

0.65 %

Price

$51.33

$13.71

Size

$36.301 million

$233.803 million

10Y return

N/A

-45.38 %

Annual distribution yield (5Y)

4.24 %

9.09 %

Market

ASX

ASX

First listed date

12/11/2018

03/11/2014

Purchase fee

$6.50

$6.50


Community Stats

CURE

HVST

Popularity

Low

Low

Pearlers invested

83

52

Median incremental investment

$619.50

$993.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$3,228.71

Average age group

> 35

> 35


Pros and Cons

CURE

HVST

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher exposure to AU market

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to AU market

  • Lower price growth

  • Lower distribution yield

  • Lower exposure to US market

  • Higher management fee

CURE

HVST

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home